Loading...
•
Apr 01, 2023
USANA Q1 2023 Earnings Report
USANA's first quarter net sales and diluted EPS were reported.
Key Takeaways
USANA Health Sciences reported a decrease in net sales and diluted EPS compared to Q1 2022, but an increase sequentially. Net sales were $248 million and diluted EPS was $0.95. The company has raised the lower end of its net sales and earnings per share guidance for fiscal year 2023.
Net sales were $248 million, a 9% decrease compared to Q1 2022 but a 9% increase sequentially.
Diluted EPS was $0.95, a 17% decrease compared to Q1 2022 but a 44% increase sequentially.
Operating cash flow was $13 million for the quarter.
Fiscal year 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively.
Revenue by Geographic Location
Forward Guidance
The company is raising the lower end of its net sales and earnings per share outlook for fiscal year 2023 due to the performance in the first quarter.
Positive Outlook
- Sales during the first few weeks of the quarter benefited by approximately $12 million due to higher demand for several of our health products in China.
- Sales benefited by an estimated $13 million in customer purchasing activity ahead of announced price increases.
- Revised consolidated net sales guidance is $875 - $950 million.
- Revised diluted EPS guidance is $2.40 - $3.30.
- The company is raising the lower end of its guidance range for both net sales and earnings per share as a result of the performance in the first quarter.
Challenges Ahead
- Fiscal 2023 outlook continues to reflect a wider range due to the continued uncertainty surrounding the operating and geopolitical environment around the world.
- Net sales decreased by 9% compared to Q1 2022.
- Diluted EPS decreased by 17% compared to Q1 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...